Furthermore, S100A16 acted as a negative regulator of the Hippo signaling pathway to assist in glioma proliferation, invasion and migration, the mechanism by which was probably to interact with and promote CUL4A, an E3 ubiquitin ligase binding to LATS1 and induce its ubiquitination degradation, which resulted in YAP/TAZ entry into the nucleus, targeting the downstream genes CTGF and CYR61. The gene discussed is LATS1; the disease is central nervous system cancer.